Aligos TherapeuticsALGS -2.22%37 EV-to-EBITDA is 0.10 as of Jul. 12, 2026, which is 66% below its 10-year median of 0.29. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.77 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 392 Biotechnology companies, Aligos Therapeutics ranks better than 96.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aligos Therapeutics's enterprise value is $-9.53 Mil.
Aligos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-92.52 Mil. Therefore, Aligos Therapeutics's EV-to-EBITDA for today is 0.10.
The historical rank and industry rank for Aligos Therapeutics's EV-to-EBITDA or its related term are showing as below:
ALGS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.45 Med: 0.29 Max: 1.13
Current: 0.1
During the past 8 years, the highest EV-to-EBITDA of Aligos Therapeutics was 1.13. The lowest was -10.45. And the median was 0.29.
ALGS's EV-to-EBITDA is ranked better than 96.43% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs ALGS: 0.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aligos Therapeutics's PE Ratio (TTM) for today is calculated as:
Aligos Therapeutics's share price for today is $6.63.
Aligos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aligos Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aligos Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's EV-to-EBITDA falls into.
Aligos Therapeutics's current Enterprise Value is $-9.53 Mil.
Aligos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (ALGS) has a EV-to-EBITDA of 0.10 as of Jul. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aligos Therapeutics. This is 66% below median its historical median of 0.29. According to the industry distribution chart, Aligos Therapeutics ranks #14 out of 392 companies in the Biotechnology industry, placing it in the top 3.6%.
Is Aligos Therapeutics' EV-to-EBITDA too high?
Aligos Therapeutics' current EV-to-EBITDA of 0.10 is 66% below median its 10-year median of 0.29. The Biotechnology industry median EV-to-EBITDA is 12.94. Aligos Therapeutics' value of 0.10 is 99.2% below this industry median. Based on the distribution chart, Aligos Therapeutics ranks #14 out of 392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' EV-to-EBITDA compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #14 out of 392 companies for EV-to-EBITDA. This places Aligos Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.94. Aligos Therapeutics' value of 0.10 is 99.2% below this benchmark. While the company's 10-year median is 0.29 vs. the industry median of 12.94, Aligos Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current EV-to-EBITDA of 0.10 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aligos Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current EV-to-EBITDA is 0.10, which is 66% below median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.77, compared to a current price of $6.63 — trading 139.4% above its estimated fair value. The current EV-to-EBITDA is 0.10, which is 66% below median its 10-year median of 0.29 and 99.2% below the Biotechnology industry median of 12.94. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current EV-to-EBITDA is 0.10 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of $6.63 is trading 139.4% above its estimated GF Value™ of $2.77.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for ALGS:
EV-to-EBITDA: 0.10 (66% below median its 10-year median of 0.29)
GF Value™: $2.77 vs. price of $6.63 (139.4% above fair value)
Industry Position: 99.2% below the Biotechnology median (#14 of 392)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score
Get the complete analysis for ALGS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
